COMPANY UPDATEPT ENSEVAL PUTERA MEGATRADING TBK.
Ended June 30, 2014 (Unaudited)
Passion For Excellence:
The Journey to Excellence
TABLE OF CONTENT
SECTION 1 Enseval In Brief 3
SECTION 2 Business Overview 8
SECTION 3 Operational Overview 20
SECTION 4 Financial Overview 23
SECTION 5 2014 Overview 28
SECTION 1ENSEVAL IN BRIEF
ENSEVAL IN BRIEF
4
Established in October 1973 with the aim of managing the distribution function because of theseparation of the distribution division from the marketing and production division of PT KalbeFarma;
On 1 August 1994, the Company listed its shares on the Jakarta Stock Exchange; The Company focuses its activities on distribution and trading services under 5 divisions :
Pharmaceutical products sales and distribution, which comprised of patented medicines as wellas generic medicines;
Consumer products, non prescription medicine and nutrition sales and distribution; Medical equipment sales and distribution, which include marketing activities; Raw material sales and distribution, which include veterinary product; Healthcare services.
Integrated healthcare Distribution and Logistic services company through Service Excellence, Technology Driven and Strong Leadership.
5
1973 – Incorporation of PT Enseval
1988 – Incorporation of PT Arya Gupta Cempaka
1993 – PT Arya Gupta Cempaka changed its name to PT EnsevalPutera Megatrading
1994 – PT Enseval Putera Megatrading Tbk conducted its Initial Public Offering
2003 – Incorporation of PT Millenia Dharma Insani
2007 – Incorporation of PT Enseval Medika Prima and PT Global Chemindo Megatrading
2008 – Incorporation of PT Renalmed Tiara Utama
2011 – The Company Right Issue to finance expansion
2012 – Obtained ISO 9001:2008 certification
2013 – Makassar, Bandung and Bekasi awarded – BPOM awards these centres for Good Distribution Practice in Pharmaceuticals.
More than 40 years in business, Enseval constanly makes the best effort to obtain sustainable growth.
ENSEVAL IN BRIEF
ENSEVAL IN BRIEF
6
Currently, the Company owns and operates 45 branches and 23 branches under subsidiaries locatedthroughtout in Indonesia;
The Company also owns 2 Regional Distribution Center (RDC) located in Jakarta and Surabaya; For the information technology platform, the Company now is using Oracle E-Business Suite Release
12; Until the end of june 2014, the Company's operation supported by over than 7,300 employees.
Become Market Leader Through high quality of information Technology system and competent human resources.
Award & Sertification Until June 2014
2014 OVERVIEW
7
• ORACLE - EXA Trend-Setter Award.
• FRONTIER - The Best Building and Managing Corporate Image.
• FROST & SULLIVAN - Indonesia Pharmaceutical Distributor of the year.
• HERMINA HOSPITAL GROUP - The Best Pharmaceutical Distributor.
• NIVEA - The Best Weighted Distributor.
• Rekor Bisnis Indonesia - Pharmaceutical Distributor with the Most Outlet Coverage.
• The Most Powerful Distribution Performance– EXTRA JOSS
– KOMIX
8
• AZ/NZS ISO 9001:2008 Certified
• BS OHSAS 18001:2007 Certified
• Good Distribution Practices Certified
• Cara Distribusi Obat yang Baik (CDOB Certified)
Award & Sertification Until June 2014
2014 OVERVIEW
SECTION 2BUSINESS OVERVIEW
*Description of net sales per products as describe below :
BUSINESS OVERVIEW
Net Sales per Products until June 30, 2014
10
Products Portfolio Net Sales (Rp)Contribution to Total Net
Sales
Consumer Products 3,664,865,320,957 44.60%
Prescription Medicines 2,340,888,691,551 28.49%
Non Prescription Medicines 1,289,486,567,822 15.69%
Raw Materials 670,090,472,482 8.15%
Medical devices 226,987,925,432 2.76%
Veterinary Products 22,037,426,734 0.27%
Health Care Services 2,823,368,056 0.03%
Total : 8,217,179,773,034 100%
BUSINESS OVERVIEW
Description of Net Sales per Products and The Contribution
11
Consumer Products
Rp3,664.86 billion44.60%
Prescription Medicines
Rp. 2,340.89 billion28.49%
Non Prescription
Medicines
Rp1,289.49 billion15.69%
Raw MaterialsRp670.09 billion
8.15%
Medical DevicesRp226.99 billion
2.76%
Veterinary Products
Rp22.04 billion0.27%
Health Care Services
Rp2.82 billion0.03%
Net Sales June 2014
Rp8,217.18 billion
*Growth of net sales per products as describe below :
BUSINESS OVERVIEW
All Business Line of the company were grew significantly
12
Products Portfolio Net Sales June 2014 (Rp) Net Sales June 2013 (Rp) Growth
Consumer Products 3,664,865,320,957 3,201,750,702,347 14.46%
Prescription Medicines 2,340,888,691,551 2,098,782,830,707 11.54%
Non Prescription Medicines 1,289,486,567,822 1,159,255,253,221 11.23%
Raw Materials 670,090,472,482 515,259,034,715 30.05%
Medical devices 226,987,925,432 282,284,496,196 -19.59%
Veterinary Products 22,037,426,734 20,141,529,593 9.41%
Health Care Services 2,823,368,056 1,915,484,751 47.40%
Total : 8,217,179,773,034 7,279,389,331,530 12.88%
Total NetSales
ConsumerProducts
PrescriptionMedicines
NonPrescriptionMedicines
Raw Materials MedicalDevices
VeterinaryProducts
Health CareServices
2013 2014
11.54 %
11.23 %
30.05 %-19.59 %
BUSINESS OVERVIEW
Growth of Net Sales 2013 vs 2014
13
12.88 %
9.41 % 47.40 %
14.46 %
BUSINESS OVERVIEW
The Company’s Principals
14
Non-Prescription
Prescription
Consumer Health
Tata Nutrisiana
BUSINESS OVERVIEW
The Company’s Principals
15
Medical Device & Diagnostic
BUSINESS OVERVIEW
The Company’s Principals
16
Raw material
Friesland Foods Domo
45 Branch 23 Branch TSJ 37 Subdist KDS/Regular 21 Sales Offices
BUSINESS OVERVIEW
National Coverage 65 Full Services Branches & More than 200,000 Direct Outlet Coverage
ENSEVAL Coverage
Type of outlet coveraged by the company’s distribution
Covers all trade channels in the market :
BUSINESS OVERVIEW
More than 200,000 direct outlet coverage
18
General / Traditional Trade Channel
• Wholesalers
• Retailers
• Provision Stores
• Convenience Stores
• Food & Beverage
• Store - Fruit Shops
• Cosmetic Stores
• etc
Modern Trade Channel
• Hypermarkets
• Supermarkets
• Mini Markets
• Departement Stores
• etc
Pharmaceutical Trade Channel
• Pharmacies
• Drugstores
• Hospitals
• Labs – Clinics
• Institutions
• etc
2014 OVERVIEW
19
Sales Contribution by Channel (June 2013 vs june 2014)
40%
32%
28%
2013
Pharmaceutical Trade
General Trade
Modern Trade
24%
39%
37%
2014
Pharmaceutical Trade
General Trade
Modern Trade
2014 OVERVIEW
20
Sales Contribution by Principal (June 2013 vs june 2014)
33.33%
66.67%
2012
External Principal Internal Principal
33.33%
66.67%
2013
External Principal Internal Principal
BUSINESS OVERVIEW
The Company’s modern trade account
21
BUSINESS OVERVIEW
200,000+ Direct Outlet Coverage
22
Pharmacy; 11.571
Hospital; 1.614
Drugstore, 4,485
Wholesaler; 2.260
Hypermarket, 178
Supermarket; 1.179
Minimarket, 3,115
Provision Store; 162.000
F&B Stores; 15.000
Cosmetics; 1.750
Others; 9.800
Covers all trade channels in the market:
- General / Traditional Trade Channel: Wholesalers, Retailers, Provision Stores, Convenience Stores, Food & Beverage Stores, Fruit Shops, Cosmetics Stores, etc
- Modern Trade Channel: Hypermarkets, Supermarkets, Mini Markets, Department Stores, etc
- Ethical Trade Channel: Pharmacies, Drugstores, Hospitals, Labs - Clinics, Institutions, etc
SECTION 3OPERATIONAL OVERVIEW
OPERATIONAL OVERVIEW
24
Mobile application (Tablet Computer & PDA)
- Supervisor: Team Performance Analysis
- Salesman & Deliveryman: Faster Order Taking & Faster Information Process
Global Information System (GIS)
- Application for more in depth sales and territory mapping .
Supported by Enseval Customer Care (ECC)
- in Branches Order Management, Complaint Handling, Basic Product Information .
Customers also can reach Enseval office via Phone, Fax & Email for easy customer ordering.
OPERATIONAL OVERVIEW
25
Centralized IT system using Oracle E-Business Solutions• Integrated & Real Time system
Use the best world-class ERP system by Oracle Complete Oracle E-Business SuiteOracle Warehouse Management System (WMS)Advance Supply Chain Planning (ASCP) and Oracle Demantra
Tablet Computer & PDA system E-Mobile ®2,300+ PDA used by Supervisors, Salesmen, Deliverymen, & Collectors Menu: Distribution Plan, Distribution Achievement, Overdue, etc
Provide data security for antivirus by Trend Micro and Sonic Wall
IT Infrastructure
OPERATIONAL OVERVIEW
26
• ENI (Enseval Net Info) • Web based application
• Sales (hourly updated) & Stock (D-1)
• EXI (Enseval Xpress Info)• SMS based application
• Sales & Stock Report
• ERI (Enseval Raw Data Info)• Raw Data format, distribution and logistics information activities
• ENO (Enseval NET Order)
• Online order with business-to-business system
For Principal
For Customer
Comprehensive Business Access
SECTION 4FINANCIAL OVERVIEW
FINANCIAL OVERVIEW
Net Sales Growth
28
7,279.39 6,497.378,217.18 7,311.16
2013 2014
89.26%88.97%
- 0.28%
12.88%12.52%
: Net Sales 30 June 2013 in Rp/billion : COGS 30 June 2013 in Rp/billion
: Net Sales 30 June 2014 in Rp/billion : COGS 30 June 2014 in Rp/billion
: COGS Margin
Net Sales COGS
30 June 2013 (Unaudited)
30 June 2014 (Unaudited)
30 June 2013 (Unaudited)
30 June 2014 (Unaudited)
782.02
906.02
FINANCIAL OVERVIEW
Expense Ratio
29
15.86%
30 June 2013 (Unaudited)
30 June 2014 (Unaudited)
Gross Profit
Gross Profit Margin
Gross Profit (Rp/Billion)
10.74%11.03%0.28%
437.98
498.31
13.77%
30 June 2013 (Unaudited)
30 June 2014 (Unaudited)
Operational Expense
Operational Expense Margin
Operational Expense (Rp/Billion)
6.85%
5.34%
-1.50%
FINANCIAL OVERVIEW
Profit Growth (Juni 2013 vs Juni 2014)
30
283.71 292.11218.05
281.79 298.94219.20
0.68% 2.34%
0.53%
Operating Profit Margin Income Before Tax Expense Margin
Income For The Year Margin
30 June 2013 (Unaudited)
30 June 2014 (Unaudited)
30 June 2013 (Unaudited)
30 June 2014 (Unaudited)
30 June 2013 (Unaudited)
30 June 2014 (Unaudited)
3.90%3.43%
-0.47%
Operating Profit(Rp/Billion)
Income Before Tax Expense (Rp/Billion)
Operating Profit Income Before Tax Expense Income For The Year
4.01%3.64%
-0.37% 3.00%2.67%
-0.33%
FINANCIAL OVERVIEW
Financial Position (December 2013 vs June 2014)
31
5,528.07
2,489.22 3,038.85
5,909.19
2,649.62 3,259.56
6.89%
6.44%7.26%
31 Dec 2013 (Audited)
30 June 2014 (Unaudited)
Total Assets (Rp/Billion) Total Liabilities (Rp/Billion)
31 Dec 2013 (Audited)
30 June 2014 (Unaudited)
31 Dec 2013 (Audited)
30 June 2014(Unaudited)
SECTION 52014 OVERVIEW
Warehouse Management System-Oracle-based WMS
-Manage stock from
inbound-outbound,
by location, SKU, Batch Number,
Expiry Date
-Bar-coding system with mobile bar-code reader to eliminate duplication & increase accurate operation
Cold Chain Management-Enseval has implemented and Standardized Cold Chain Management in it’s RDC, Branch Warehouse, and Transportation according to ISO 9001:2008.
-Cold Chain Management is performed with close control
-All activities is always recorded and stored properly
Cold Chain Handling in Enseval Delivery with Temperature Controlled Transportation
Temperature MonitoringDocument
Standardized FacilitiesStandardized Branches (Full Services)
Standardized FacilitiesStandardized Branches (Full Services)
Strategic Value to Business Partners• Strong product portfolio.
• Sustainable business growth.
• Supported by 2 RDC, 45 branches, 13 Sales Office, & 200,000+ direct coverage outlets.
Market Leading Position in Indonesia
• 40+ years of strategic expertise in distribution and logistics service.
• Strong and good relationship with all business players : Principals & Outlets.
• Having in aggregate over 100 years of experience senior management team and supported by more than 5000 employees.
Reliable Partner to Grow
• Public listed company with professional management that treats all business partners equally with the utmost transparency and accountability.
• Independent business entity with neutrality to ensure fairness to all stakeholders.Transparency and Neutrality
• Robust balance sheet figures.
• Solid financial performance.Strong Financial Track Record
• Commitment to assist & support Principal to achieve it’s goals.
• Implementation of Continuous Improvement (CONIM) in all business aspects by Enseval’s employees in every level.
Enseval’s Commitment Towards Improvement
FORWARD LOOKING STATEMENTThis presentation has been prepared for informational purposes only by PT Enseval Putera Megatrading Tbk. ("Enseval" or the "Company")
This presentation has been prepared solely for use in connection with the release 0f 30 june 2013 unaudited results of the Company. The information containedin this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance shouldbe placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of theirrespective affiliates, and their respective commissioners, directors and employees, advisors or representative shall have any liability whatsoever (in negligenceor otherwise) for any loss however arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Anydecision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation.The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or anexemption from registration.This presentation and its contents are confidential unless they are become generally avaiable as public information in accordance with prevailing lawsregulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by receipentsto any other person. This presentation does not constitute a recommendation regarding the securities of the Company.This presentation, including the information and opinions contained herein, is provided as the date of this presentation and is subject to change without notice,including change as a result of the issuance of 30 June 2013 unaudited results of the Company.This presentation includes "forward-looking statements". These statements contain the words "anticipate", "believe", "intend", "estimate", "expect" and wordsof similiar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding theCompany's financial position, business strategy, plans and objectives of management for future operations (including development plans, objectives relating tothe Company's products and services and anticipated product launches) are forward-looking statements. Such forward-looking statements are based onnumerous assumptions regarding the Company's present and future business strategies and the environment in which of the Company will operate in thefuture. These forward-looking statements speak only ast the date of this presentation. The Company expressly disclaims any obligation or reflection of anychange in the Company's expectations with regard thereto, or any change in events, conditions or circumtances on which any statements is based.Market data and certain industry forecast used in this presentation were obtained from market research, publicity avaiable information and industrypublications which have not been independently verified, and no presentation is made as to the accuracy of such information.
THANK YOUFor Further Information:
Corporate SecretaryPT Enseval Putera Megatrading Tbk.Enseval BuildingKawasan Industri PulogadungJalan Pulolentut No. 10Jakarta 13920 – IndonesiaPhone : 62-21-46822422 Fax : 62-21-4609039Website : www.enseval.comEmail : [email protected]